Unexpected gastrointestinal toxicity from Docetaxel/Carboplatin/Erlotinib followed by maintenance Erlotinib treatment for newly diagnosed stage III/IV ovarian cancer, primary peritoneal, or fallopian tube cancer

scientific article published on 15 February 2011

Unexpected gastrointestinal toxicity from Docetaxel/Carboplatin/Erlotinib followed by maintenance Erlotinib treatment for newly diagnosed stage III/IV ovarian cancer, primary peritoneal, or fallopian tube cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.YGYNO.2010.11.049
P698PubMed publication ID21324515

P50authorBarbara A. GoffQ79148245
P2093author name stringLeona A Holmberg
Dan Veljovich
P2860cites workDocetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancerQ28346751
Are DNA ploidy and epidermal growth factor receptor prognostic factors for untreated ovarian cancer? A prospective studyQ74015417
P433issue2
P921main subjectovarian cancerQ172341
erlotinibQ418369
fallopian tube carcinomaQ18554948
uterine tubeQ1233836
fallopian tube cancerQ4818922
P304page(s)426
P577publication date2011-02-15
P1433published inGynecologic OncologyQ5625182
P1476titleUnexpected gastrointestinal toxicity from Docetaxel/Carboplatin/Erlotinib followed by maintenance Erlotinib treatment for newly diagnosed stage III/IV ovarian cancer, primary peritoneal, or fallopian tube cancer
P478volume121

Reverse relations

cites work (P2860)
Q33637787Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells
Q98164379Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence
Q34306004Transactivation of epidermal growth factor receptor through platelet-activating factor/receptor in ovarian cancer cells

Search more.